Synergy Pharmaceuticals Announces Positive Results in First Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

NEW YORK--(BUSINESS WIRE) December 9, 2016 -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, an...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news